Although the corresponding frequencies of K-ras and PIK3CA mutations are approximately 5%-15% and 3%-5%15,16, many studies have reported that K-ras and PIK3CA mutations may have primarily induced resistance to EGFR-TKIs of NSCLC patients17,.18 This evidence concerns the gene KRAS and non-small cell lung carcinoma.